159 related articles for article (PubMed ID: 20064705)
1. Plasma 25-hydroxyvitamin D and prostate cancer risk: the multiethnic cohort.
Park SY; Cooney RV; Wilkens LR; Murphy SP; Henderson BE; Kolonel LN
Eur J Cancer; 2010 Mar; 46(5):932-6. PubMed ID: 20064705
[TBL] [Abstract][Full Text] [Related]
2. Serum zinc and prostate cancer risk in a nested case-control study: The multiethnic cohort.
Park SY; Wilkens LR; Morris JS; Henderson BE; Kolonel LN
Prostate; 2013 Feb; 73(3):261-6. PubMed ID: 22851289
[TBL] [Abstract][Full Text] [Related]
3. Serum vitamin D concentration and prostate cancer risk: a nested case-control study.
Ahn J; Peters U; Albanes D; Purdue MP; Abnet CC; Chatterjee N; Horst RL; Hollis BW; Huang WY; Shikany JM; Hayes RB;
J Natl Cancer Inst; 2008 Jun; 100(11):796-804. PubMed ID: 18505967
[TBL] [Abstract][Full Text] [Related]
4. Serum 25-hydroxyvitamin D, vitamin D binding protein, and prostate cancer risk in black men.
Layne TM; Weinstein SJ; Graubard BI; Ma X; Mayne ST; Albanes D
Cancer; 2017 Jul; 123(14):2698-2704. PubMed ID: 28369777
[TBL] [Abstract][Full Text] [Related]
5. Plasma 25-hydroxyvitamin D3 is associated with decreased risk of postmenopausal breast cancer in whites: a nested case-control study in the multiethnic cohort study.
Kim Y; Franke AA; Shvetsov YB; Wilkens LR; Cooney RV; Lurie G; Maskarinec G; Hernandez BY; Le Marchand L; Henderson BE; Kolonel LN; Goodman MT
BMC Cancer; 2014 Jan; 14():29. PubMed ID: 24438060
[TBL] [Abstract][Full Text] [Related]
6. Plasma 25-hydroxyvitamin D levels and the risk of colorectal cancer: the multiethnic cohort study.
Woolcott CG; Wilkens LR; Nomura AM; Horst RL; Goodman MT; Murphy SP; Henderson BE; Kolonel LN; Le Marchand L
Cancer Epidemiol Biomarkers Prev; 2010 Jan; 19(1):130-4. PubMed ID: 20056631
[TBL] [Abstract][Full Text] [Related]
7. Levels of beta-microseminoprotein in blood and risk of prostate cancer in multiple populations.
Haiman CA; Stram DO; Vickers AJ; Wilkens LR; Braun K; Valtonen-André C; Peltola M; Pettersson K; Waters KM; Marchand LL; Kolonel LN; Henderson BE; Lilja H
J Natl Cancer Inst; 2013 Feb; 105(3):237-43. PubMed ID: 23213189
[TBL] [Abstract][Full Text] [Related]
8. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States).
Nomura AM; Stemmermann GN; Lee J; Kolonel LN; Chen TC; Turner A; Holick MF
Cancer Causes Control; 1998 Aug; 9(4):425-32. PubMed ID: 9794175
[TBL] [Abstract][Full Text] [Related]
9. Plasma 25-hydroxy vitamin D and subsequent prostate cancer risk in a nested Case-Control study in Japan: The JPHC study.
Sawada N; Inoue M; Iwasaki M; Yamaji T; Shimazu T; Sasazuki S; Tsugane S
Eur J Clin Nutr; 2017 Jan; 71(1):132-136. PubMed ID: 27759068
[TBL] [Abstract][Full Text] [Related]
10. Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC).
Travis RC; Crowe FL; Allen NE; Appleby PN; Roddam AW; Tjønneland A; Olsen A; Linseisen J; Kaaks R; Boeing H; Kröger J; Trichopoulou A; Dilis V; Trichopoulos D; Vineis P; Palli D; Tumino R; Sieri S; Bueno-de-Mesquita HB; van Duijnhoven FJ; Chirlaque MD; Barricarte A; Larrañaga N; González CA; Argüelles MV; Sánchez MJ; Stattin P; Hallmans G; Khaw KT; Bingham S; Rinaldi S; Slimani N; Jenab M; Riboli E; Key TJ
Am J Epidemiol; 2009 May; 169(10):1223-32. PubMed ID: 19359375
[TBL] [Abstract][Full Text] [Related]
11. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer.
Platz EA; Leitzmann MF; Hollis BW; Willett WC; Giovannucci E
Cancer Causes Control; 2004 Apr; 15(3):255-65. PubMed ID: 15090720
[TBL] [Abstract][Full Text] [Related]
12. A Collaborative Analysis of Individual Participant Data from 19 Prospective Studies Assesses Circulating Vitamin D and Prostate Cancer Risk.
Travis RC; Perez-Cornago A; Appleby PN; Albanes D; Joshu CE; Lutsey PL; Mondul AM; Platz EA; Weinstein SJ; Layne TM; Helzlsouer KJ; Visvanathan K; Palli D; Peeters PH; Bueno-de-Mesquita B; Trichopoulou A; Gunter MJ; Tsilidis KK; Sánchez MJ; Olsen A; Brenner H; Schöttker B; Perna L; Holleczek B; Knekt P; Rissanen H; Yeap BB; Flicker L; Almeida OP; Wong YYE; Chan JM; Giovannucci EL; Stampfer MJ; Ursin G; Gislefoss RE; Bjørge T; Meyer HE; Blomhoff R; Tsugane S; Sawada N; English DR; Eyles DW; Heath AK; Williamson EJ; Manjer J; Malm J; Almquist M; Marchand LL; Haiman CA; Wilkens LR; Schenk JM; Tangen CM; Black A; Cook MB; Huang WY; Ziegler RG; Martin RM; Hamdy FC; Donovan JL; Neal DE; Touvier M; Hercberg S; Galan P; Deschasaux M; Key TJ; Allen NE
Cancer Res; 2019 Jan; 79(1):274-285. PubMed ID: 30425058
[TBL] [Abstract][Full Text] [Related]
13. A prospective study of plasma 25-hydroxyvitamin D concentration and prostate cancer risk.
Deschasaux M; Souberbielle JC; Latino-Martel P; Sutton A; Charnaux N; Druesne-Pecollo N; Galan P; Hercberg S; Le Clerc S; Kesse-Guyot E; Ezzedine K; Touvier M
Br J Nutr; 2016 Jan; 115(2):305-14. PubMed ID: 26568368
[TBL] [Abstract][Full Text] [Related]
14. Association between Plasma 25-Hydroxyvitamin D, Ancestry and Aggressive Prostate Cancer among African Americans and European Americans in PCaP.
Steck SE; Arab L; Zhang H; Bensen JT; Fontham ET; Johnson CS; Mohler JL; Smith GJ; Su JL; Trump DL; Woloszynska-Read A
PLoS One; 2015; 10(4):e0125151. PubMed ID: 25919866
[TBL] [Abstract][Full Text] [Related]
15. Circulating 25-hydroxyvitamin D, vitamin D binding protein and risk of advanced and lethal prostate cancer.
Yuan C; Shui IM; Wilson KM; Stampfer MJ; Mucci LA; Giovannucci EL
Int J Cancer; 2019 May; 144(10):2401-2407. PubMed ID: 30411792
[TBL] [Abstract][Full Text] [Related]
16. Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade.
Gilbert R; Metcalfe C; Fraser WD; Donovan J; Hamdy F; Neal DE; Lane JA; Martin RM
Int J Cancer; 2012 Sep; 131(5):1187-96. PubMed ID: 22033893
[TBL] [Abstract][Full Text] [Related]
17. Circulating 25-hydroxyvitamin D, vitamin D-binding protein and risk of prostate cancer.
Weinstein SJ; Mondul AM; Kopp W; Rager H; Virtamo J; Albanes D
Int J Cancer; 2013 Jun; 132(12):2940-7. PubMed ID: 23180681
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study.
Shui IM; Mucci LA; Kraft P; Tamimi RM; Lindstrom S; Penney KL; Nimptsch K; Hollis BW; Dupre N; Platz EA; Stampfer MJ; Giovannucci E
J Natl Cancer Inst; 2012 May; 104(9):690-9. PubMed ID: 22499501
[TBL] [Abstract][Full Text] [Related]
19. Circulating 25-Hydroxyvitamin D Concentration and Risk of Breast, Prostate, and Colorectal Cancers: The Melbourne Collaborative Cohort Study.
Heath AK; Hodge AM; Ebeling PR; Eyles DW; Kvaskoff D; Buchanan DD; Giles GG; Williamson EJ; English DR
Cancer Epidemiol Biomarkers Prev; 2019 May; 28(5):900-908. PubMed ID: 30842127
[TBL] [Abstract][Full Text] [Related]
20. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer.
Li H; Stampfer MJ; Hollis JB; Mucci LA; Gaziano JM; Hunter D; Giovannucci EL; Ma J
PLoS Med; 2007 Mar; 4(3):e103. PubMed ID: 17388667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
